ONCT - Oncternal Therapeutics: Improving Outcomes In 'Standard Of Care' Chemo

• Oncternal is one of the oldest companies in the ROR1 oncology space, a field fraught with recent acquisitions.
• Almost every other player in the ROR1 space has been scooped up by big pharma players, but mostly those in ADCs.
• To understand the different approaches in this niche of oncology, one must separate MABS, ADCs, and CAR-T therapy approaches.
• Regardless of the approach, this niche has deep value, and as an investment, the risks must be weighed against reward.
• The weighing of investment grade risk/reward puts Oncternal clearly in the "Winner's Corner."

For further details see: